Matteo Foschi, Damiano Marastoni, Ivan Panzera, Luca Mancinelli, Cristiana Ganino, Gianmarco Abbadessa, Lucio D'Anna, Francesca Gabriele, Simona Sacco, Elisabetta Signoriello, Alessandra Lugaresi, Elena Tsantes, Maria Grazia Piscaglia, Andrea Surcinelli
{"title":"复发缓解型多发性硬化症中复发无关和复发相关残疾进展的性别差异:一项真实世界的反概率加权研究。","authors":"Matteo Foschi, Damiano Marastoni, Ivan Panzera, Luca Mancinelli, Cristiana Ganino, Gianmarco Abbadessa, Lucio D'Anna, Francesca Gabriele, Simona Sacco, Elisabetta Signoriello, Alessandra Lugaresi, Elena Tsantes, Maria Grazia Piscaglia, Andrea Surcinelli","doi":"10.1177/17562864251376807","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Sex differences in multiple sclerosis (MS) progression are poorly characterized, especially for disability worsening independent of relapses.</p><p><strong>Objectives: </strong>To assess sex-specific risks of progression independent of relapse activity (PIRA), relapse and magnetic resonance imaging (MRI) activity (PIRMA), and relapse-associated worsening (RAW) in a real-world MS cohort, quantify each event's contribution to disability accumulation, and explore variation across clinical subgroups.</p><p><strong>Design: </strong>Inverse probability-weighted analysis of adults with relapsing-remitting MS ambispectively enrolled in a local registry who had their first recorded neurological evaluation within 12 months of MS onset.</p><p><strong>Methods: </strong>We used weighted conditional proportional hazard models for recurrent events, adjusted for visit/MRI frequency, to compare risks between sexes. We also tested the homogeneity of sex effects across prespecified subgroups: age at MS onset, symptom location at onset, presence of ⩾10 T2-hyperintense brain lesions, ⩾1 spinal T2 lesion, ⩾1 Gadolinium-enhancing brain lesion at baseline, initial MS treatment type, and percentage of follow-up time on disease-modifying therapy (DMT).</p><p><strong>Results: </strong>We included 492 people with MS (median age 44.0 years, interquartile range (IQR) 35.0-53.6; 68.9% women), followed for a median of 5.1 years (IQR 3.1-7.2). In the weighted cohort, women had higher hazards of PIRA (hazard ratio (HR) 2.44, 95% confidence interval (CI) 1.56-3.70; <i>p</i> < 0.001) and PIRMA (HR 2.13, 95% CI 1.25-3.70; <i>p</i> < 0.001), mainly postmenopausal (56.6% and 52.4%). RAW risk was similar (HR 1.07, 95% CI 0.54-2.11; <i>p</i> = 0.843), despite higher relapse rates in women (0.13 ± 0.18 vs 0.06 ± 0.16; <i>p</i> < 0.001). Men had greater Expanded Disability Status Scale worsening per PIRA (+0.29 ± 0.71 vs +0.16 ± 0.53; <i>p</i> = 0.023) and PIRMA (+0.25 ± 0.71 vs +0.09 ± 0.38; <i>p</i> = 0.001). Age ⩾50 at onset increased PIRA/PIRMA risk without sex interaction. Significant sex interaction was seen for onset symptom location (<i>p</i> < 0.001 for both outcomes) and initial DMT (<i>p</i> = 0.013 for PIRA; <i>p</i> = 0.022 for PIRMA).</p><p><strong>Conclusion: </strong>Women, especially postmenopausal, had higher PIRA/PIRMA risk, but disability worsening per event was greater in men, associations varied by onset phenotype and initial DMT strategy.</p>","PeriodicalId":22980,"journal":{"name":"Therapeutic Advances in Neurological Disorders","volume":"18 ","pages":"17562864251376807"},"PeriodicalIF":4.1000,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12457755/pdf/","citationCount":"0","resultStr":"{\"title\":\"Sex differences in relapse-independent and relapse-associated disability progression in relapsing-remitting multiple sclerosis: a real-world inverse-probability weighted study.\",\"authors\":\"Matteo Foschi, Damiano Marastoni, Ivan Panzera, Luca Mancinelli, Cristiana Ganino, Gianmarco Abbadessa, Lucio D'Anna, Francesca Gabriele, Simona Sacco, Elisabetta Signoriello, Alessandra Lugaresi, Elena Tsantes, Maria Grazia Piscaglia, Andrea Surcinelli\",\"doi\":\"10.1177/17562864251376807\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Sex differences in multiple sclerosis (MS) progression are poorly characterized, especially for disability worsening independent of relapses.</p><p><strong>Objectives: </strong>To assess sex-specific risks of progression independent of relapse activity (PIRA), relapse and magnetic resonance imaging (MRI) activity (PIRMA), and relapse-associated worsening (RAW) in a real-world MS cohort, quantify each event's contribution to disability accumulation, and explore variation across clinical subgroups.</p><p><strong>Design: </strong>Inverse probability-weighted analysis of adults with relapsing-remitting MS ambispectively enrolled in a local registry who had their first recorded neurological evaluation within 12 months of MS onset.</p><p><strong>Methods: </strong>We used weighted conditional proportional hazard models for recurrent events, adjusted for visit/MRI frequency, to compare risks between sexes. We also tested the homogeneity of sex effects across prespecified subgroups: age at MS onset, symptom location at onset, presence of ⩾10 T2-hyperintense brain lesions, ⩾1 spinal T2 lesion, ⩾1 Gadolinium-enhancing brain lesion at baseline, initial MS treatment type, and percentage of follow-up time on disease-modifying therapy (DMT).</p><p><strong>Results: </strong>We included 492 people with MS (median age 44.0 years, interquartile range (IQR) 35.0-53.6; 68.9% women), followed for a median of 5.1 years (IQR 3.1-7.2). In the weighted cohort, women had higher hazards of PIRA (hazard ratio (HR) 2.44, 95% confidence interval (CI) 1.56-3.70; <i>p</i> < 0.001) and PIRMA (HR 2.13, 95% CI 1.25-3.70; <i>p</i> < 0.001), mainly postmenopausal (56.6% and 52.4%). RAW risk was similar (HR 1.07, 95% CI 0.54-2.11; <i>p</i> = 0.843), despite higher relapse rates in women (0.13 ± 0.18 vs 0.06 ± 0.16; <i>p</i> < 0.001). Men had greater Expanded Disability Status Scale worsening per PIRA (+0.29 ± 0.71 vs +0.16 ± 0.53; <i>p</i> = 0.023) and PIRMA (+0.25 ± 0.71 vs +0.09 ± 0.38; <i>p</i> = 0.001). Age ⩾50 at onset increased PIRA/PIRMA risk without sex interaction. Significant sex interaction was seen for onset symptom location (<i>p</i> < 0.001 for both outcomes) and initial DMT (<i>p</i> = 0.013 for PIRA; <i>p</i> = 0.022 for PIRMA).</p><p><strong>Conclusion: </strong>Women, especially postmenopausal, had higher PIRA/PIRMA risk, but disability worsening per event was greater in men, associations varied by onset phenotype and initial DMT strategy.</p>\",\"PeriodicalId\":22980,\"journal\":{\"name\":\"Therapeutic Advances in Neurological Disorders\",\"volume\":\"18 \",\"pages\":\"17562864251376807\"},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2025-09-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12457755/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Neurological Disorders\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/17562864251376807\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Neurological Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562864251376807","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:多发性硬化症(MS)进展的性别差异特征不明显,特别是独立于复发的残疾恶化。目的:评估真实世界MS队列中独立于复发活动(PIRA),复发和磁共振成像(PIRMA)活动(PIRMA)以及复发相关恶化(RAW)的性别特异性进展风险,量化每种事件对残疾积累的贡献,并探索临床亚组之间的变化。设计:对在当地登记的双侧复发-缓解型多发性硬化症患者进行逆概率加权分析,这些患者在多发性硬化症发病后12个月内进行了首次神经学评估。方法:我们使用加权条件比例风险模型对复发事件进行加权,并根据就诊/MRI频率进行调整,比较不同性别之间的风险。我们还在预先指定的亚组中测试了性别效应的同质性:MS发病时的年龄,发病时的症状位置,在基线处存在大于或等于10 T2高强度脑病变,大于或等于1脊髓T2病变,大于或等于1钆增强脑病变,初始MS治疗类型,以及疾病修饰治疗(DMT)的随访时间百分比。结果:纳入492例多发性硬化症患者(中位年龄44.0岁,四分位数间距(IQR) 35.0-53.6;68.9%为女性),随访中位数为5.1年(IQR为3.1-7.2)。在加权队列中,女性患PIRA的风险较高(风险比(HR) 2.44, 95%可信区间(CI) 1.56 ~ 3.70;p p p = 0.843),尽管妇女中较高的复发率(0.13±0.18 vs 0.06±0.16;p p = 0.023)和PIRMA(+ 0.25±0.71 vs 0.09±0.38;p = 0.001)。发病时年龄大于或等于50岁在没有性别相互作用的情况下增加了PIRA/PIRMA风险。在发病症状位置上,两性之间存在显著的相互作用(PIRA组p = 0.013, PIRMA组p = 0.022)。结论:女性,尤其是绝经后,有更高的PIRA/PIRMA风险,但男性每次事件的残疾恶化更大,其相关性因发病表型和初始DMT策略而异。
Sex differences in relapse-independent and relapse-associated disability progression in relapsing-remitting multiple sclerosis: a real-world inverse-probability weighted study.
Background: Sex differences in multiple sclerosis (MS) progression are poorly characterized, especially for disability worsening independent of relapses.
Objectives: To assess sex-specific risks of progression independent of relapse activity (PIRA), relapse and magnetic resonance imaging (MRI) activity (PIRMA), and relapse-associated worsening (RAW) in a real-world MS cohort, quantify each event's contribution to disability accumulation, and explore variation across clinical subgroups.
Design: Inverse probability-weighted analysis of adults with relapsing-remitting MS ambispectively enrolled in a local registry who had their first recorded neurological evaluation within 12 months of MS onset.
Methods: We used weighted conditional proportional hazard models for recurrent events, adjusted for visit/MRI frequency, to compare risks between sexes. We also tested the homogeneity of sex effects across prespecified subgroups: age at MS onset, symptom location at onset, presence of ⩾10 T2-hyperintense brain lesions, ⩾1 spinal T2 lesion, ⩾1 Gadolinium-enhancing brain lesion at baseline, initial MS treatment type, and percentage of follow-up time on disease-modifying therapy (DMT).
Results: We included 492 people with MS (median age 44.0 years, interquartile range (IQR) 35.0-53.6; 68.9% women), followed for a median of 5.1 years (IQR 3.1-7.2). In the weighted cohort, women had higher hazards of PIRA (hazard ratio (HR) 2.44, 95% confidence interval (CI) 1.56-3.70; p < 0.001) and PIRMA (HR 2.13, 95% CI 1.25-3.70; p < 0.001), mainly postmenopausal (56.6% and 52.4%). RAW risk was similar (HR 1.07, 95% CI 0.54-2.11; p = 0.843), despite higher relapse rates in women (0.13 ± 0.18 vs 0.06 ± 0.16; p < 0.001). Men had greater Expanded Disability Status Scale worsening per PIRA (+0.29 ± 0.71 vs +0.16 ± 0.53; p = 0.023) and PIRMA (+0.25 ± 0.71 vs +0.09 ± 0.38; p = 0.001). Age ⩾50 at onset increased PIRA/PIRMA risk without sex interaction. Significant sex interaction was seen for onset symptom location (p < 0.001 for both outcomes) and initial DMT (p = 0.013 for PIRA; p = 0.022 for PIRMA).
Conclusion: Women, especially postmenopausal, had higher PIRA/PIRMA risk, but disability worsening per event was greater in men, associations varied by onset phenotype and initial DMT strategy.
期刊介绍:
Therapeutic Advances in Neurological Disorders is a peer-reviewed, open access journal delivering the highest quality articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of neurology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in neurology, providing a forum in print and online for publishing the highest quality articles in this area.